Literature DB >> 214795

Reversal of renovascular hypertension by antibodies specific for angiotensin-converting enzyme.

R A Markle, E H Sonnenblick, J M Conroy, R L Soffer.   

Abstract

Goat antibodies developed against pure rabbit pulmonary angiotensin-converting enzyme (peptidyl dipeptidase, EC 3.4.15.1) were administered intravenously to rats with two-kidney Goldblatt hypertension and to normotensive animals. In the hypertensive model these antibodies were associated with a sustained, immune-dependent decrease of blood pressure to normal values. A smaller, but also immune-specific, reduction of blood pressure was observed in the normotensive group. The data suggest that heterologous antibody directed against angiotensin-converting enzyme may provide a biologically specific probe for examining the contribution of the renin-angiotensin system to normal and pathologic circulatory states.

Entities:  

Mesh:

Substances:

Year:  1978        PMID: 214795      PMCID: PMC393036          DOI: 10.1073/pnas.75.11.5702

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  31 in total

1.  A BRADYKININ-POTENTIATING FACTOR (BPF) PRESENT IN THE VENOM OF BOTHROPS JARARCA.

Authors:  S H FERREIRA
Journal:  Br J Pharmacol Chemother       Date:  1965-02

2.  Hypotensive agents and pressor substances. The effect of epinephrine, norepinephrine, angiotensin II, and others on the secretory rate of aldosterone in man.

Authors:  J H LARAGH; M ANGERS; W G KELLY; S LIEBERMAN
Journal:  JAMA       Date:  1960-09-17       Impact factor: 56.272

3.  Angiotensin-converting enzyme: effect of antienzyme antibody in vivo.

Authors:  P R Caldwell; H J Wigger
Journal:  FEBS Lett       Date:  1976-03-15       Impact factor: 4.124

4.  Subcellular localization of pulmonary antiotensin-converting enzyme (kininase II).

Authors:  J W Ryan; U S Ryan; D R Schultz; C Whitaker; A Chung
Journal:  Biochem J       Date:  1975-02       Impact factor: 3.857

5.  Angiotensin-converting enzyme inhibitors from the venom of Bothrops jararaca. Isolation, elucidation of structure, and synthesis.

Authors:  M A Ondetti; N J Williams; E F Sabo; J Pluscec; E R Weaver; O Kocy
Journal:  Biochemistry       Date:  1971-10-26       Impact factor: 3.162

6.  Isolation of bradykinin-potentiating peptides from Bothrops jararaca venom.

Authors:  S H Ferreira; D C Bartelt; L J Greene
Journal:  Biochemistry       Date:  1970-06-23       Impact factor: 3.162

7.  Activity of various fractions of bradykinin potentiating factor against angiotensin I converting enzyme.

Authors:  S H Ferreira; L H Greene; V A Alabaster; Y S Bakhle; J R Vane
Journal:  Nature       Date:  1970-01-24       Impact factor: 49.962

8.  Reduction of pressor effects of angiotensin I in man by synthetic nonapeptide (B.P.P. 9a or SQ 20,881) which inhibits converting enzyme.

Authors:  J G Collier; B F Robinson; J R Vane
Journal:  Lancet       Date:  1973-01-13       Impact factor: 79.321

9.  Conversion of angiotensin I to angiotensin II by cell-free extracts of dog lung.

Authors:  Y S Bakhle
Journal:  Nature       Date:  1968-11-30       Impact factor: 49.962

10.  The purification of hypertensin II.

Authors:  L T SKEGGS; J R KAHN; N P SHUMWAY
Journal:  J Exp Med       Date:  1956-03-01       Impact factor: 14.307

View more
  1 in total

1.  Human lung angiotensin converting enzyme. Purification and antibody preparation.

Authors:  J Friedland; E Silverstein; M Drooker; C Setton
Journal:  J Clin Invest       Date:  1981-04       Impact factor: 14.808

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.